Tarceva filed for first-line maintenance use in lung cancer in US and EU
This article was originally published in Scrip
Executive Summary
OSI Pharmaceuticals/Genentech and Roche have submitted applications in the US and EU, respectively, for use of their EGFR-targeted small molecule drug Tarceva (erlotinib) as a first-line maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) who have not progressed following first-line treatment with platinum-based chemotherapy.